Investors
Company Overview
AXIM Biotechnologies (OTC: AXIM) is an international healthcare solutions company targeting ocular biomarkers and has been developing two highly specialized Point-of-Care (POC) lab testing solutions designed specifically to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and allergic conjunctivitis
AXIM is currently preparing a 510(k) submission to seek FDA clearance to commercialize its updated Lactoferrin diagnostic device and intends to submit a subsequent 510(k) application for its updated IgE diagnostic test.
These products are under development and have not yet received clearance from the U.S. Food and Drug Administration.
Email Alerts
Stay informed and receive company updates straight to your inbox
The press releases contained in this archive reflect information as of their original publication dates. AXIM Biotechnologies undertakes no obligation to update such information except as required by law. Current information regarding the Company’s products and regulatory status is available on this website.
Recent News
AXIM® Biotechnologies Develops Next Generation of its Rapid Neutralizing Antibody Test for COVID-19
SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological, COVID-19 and dry eye disease (DED) diagnostics, today announced the...
Investor Contact Information
Company
AXIM Biotechnologies, Inc.
6048 Cornerstone Ct. West Suite E1,
San Diego, CA 92121
T: +1 858-256-5132
Investor Relations
Transfer Agent
Action Stock Transfer Corporation
2469 E. Fort Union Blvd
Suite 214
Salt Lake City, UT 84121
T: 801-274-1088
info@actionstocktransfer.com
www.actionstocktransfer.com